Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Enzyme inhibitor limits scarring after heart attacks and protects heart function in mice (opens in a new tab)

medicalxpress.com · 2026-10-09

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 5 other points were not covered by the paper.

  • 1 supported
  • 1 overstated
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. One of seven checks out. Five claims the study doesn't address.

  • 1 supported
  • 1 overstated
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedResearchers in Japan found that the enzyme BCAT1 plays a major role in cardiac fibrosis.View evidenceHide evidence

Why this verdict

The abstract supports a causal role for BCAT1 in post-MI cardiac fibrosis in mice and provides a mechanistic pathway in fibroblast/myofibroblast experiments. However, the story's unhedged phrasing that BCAT1 plays a 'major role' in cardiac fibrosis broadly is stronger than the abstract-level evidence, which provides no effect sizes and is centered on experimental mouse MI and cellular mechanisms.

1

Study evidence

BCAT1-mediated BCAA production promoted phosphorylation of HDAC5 at Ser488, which led to increased SMAD3 phosphorylation and enhanced SMAD3-dependent transcription of the proline-biosynthesis genes Aldh18a1, Pycr1, and Eprs in protomyofibroblast-like fibroblasts and myofibroblasts.

“The production of BCAA by BCAT1 promoted SMAD3 phosphorylation via HDAC5 phosphorylation at Ser488”
2

Study evidence

In BCAT1-deficient mice, expression of proline biosynthesis–related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.

“In BCAT1-deficient mice, expression of proline biosynthesis-related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.”
Claim 2 of 7Not coveredIn mouse studies, blocking BCAT1 reduced fibrosis and preserved heart function, even after tissue damage had started.View evidenceHide evidence

Why this verdict

The abstract supports that pharmacologic BCAT1 inhibition after MI reduced cardiac fibrosis in mice. It does not verify preservation of heart function, and the profile notes that functional outcomes such as echocardiography are unclear at abstract depth. The timing is only described generally as after MI, not in the more detailed terms used by the story.

1

Study evidence

Pharmacologic BCAT1 inhibition after myocardial infarction reduced cardiac fibrosis in mice (reported in the abstract).

“mice with MI that were treated with a BCAT1 inhibitor had reduced cardiac fibrosis.”
Claim 3 of 7Not coveredMice genetically engineered to lack BCAT1 developed less scar tissue and maintained better heart function than control mice after a heart attack.View evidenceHide evidence

Why this verdict

The abstract supports that BCAT1-deficient mice had attenuated post-MI proline-biosynthesis gene expression and decreased cardiac fibrosis. It does not verify the additional claim that these mice maintained better heart function than controls.

1

Study evidence

In BCAT1-deficient mice, expression of proline biosynthesis–related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.

“In BCAT1-deficient mice, expression of proline biosynthesis-related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.”
Claim 4 of 7Not coveredThe BCAT1 inhibitor ERG240 reduced scarring and preserved heart function in mice even when treatment began seven days after injury.View evidenceHide evidence

As statedseven days after injury

Why this verdict

The abstract supports that a BCAT1 inhibitor reduced cardiac fibrosis in mice after MI. It does not identify the inhibitor as ERG240, does not report treatment beginning seven days after injury, and does not verify preserved heart function; the profile specifically notes that dosing, timing, route, and functional outcomes are not available at abstract depth.

1

Study evidence

Pharmacologic BCAT1 inhibition after myocardial infarction reduced cardiac fibrosis in mice (reported in the abstract).

“mice with MI that were treated with a BCAT1 inhibitor had reduced cardiac fibrosis.”
Claim 5 of 7Not coveredAnalysis of human heart tissue from patients with heart failure found elevated BCAT1 linked to increased fibrosis, and higher BCAT1 was also seen in livers from patients with fatty liver disease.View evidenceHide evidence

Why this verdict

The abstract supports BCAT1 upregulation in myofibroblasts in fibrotic human hearts and livers, which is broadly consistent with human-tissue relevance. But the supplied abstract-level profile does not verify the specific patient categories of heart failure and fatty liver disease, nor a quantified link between higher BCAT1 and increased fibrosis.

1

Study evidence

BCAT1 expression is reported as upregulated in a substantial subset of POSTN-expressing protomyofibroblast-like fibroblasts and in myofibroblasts in fibrotic hearts and livers of mice and humans.

“Bcat1 was upregulated in a substantial subset of Periostin (Postn)-expressing protomyofibroblast-like fibroblasts”
Claim 6 of 7Not coveredThe authors propose that targeting BCAT1 could reduce fibrosis without affecting normal tissue and may have fewer side effects than existing antifibrotic treatments.View evidenceHide evidence

Why this verdict

The abstract supports BCAT1 inhibition as a therapeutic proof of concept for reducing post-MI fibrosis in mice. It does not verify the more specific author proposal that targeting BCAT1 could reduce fibrosis without affecting normal tissue or may have fewer side effects than existing antifibrotic treatments.

1

Study evidence

Pharmacologic BCAT1 inhibition after myocardial infarction reduced cardiac fibrosis in mice (reported in the abstract).

“mice with MI that were treated with a BCAT1 inhibitor had reduced cardiac fibrosis.”
Claim 7 of 7SupportedThe study, published in the Journal of Clinical Investigation, found that BCAT1 activates a cellular pathway that maintains the supply of proline and supports large-scale collagen production.View evidenceHide evidence

Why this verdict

The abstract describes a BCAT1/BCAA-driven pathway involving HDAC5 Ser488 phosphorylation, SMAD3 phosphorylation, and SMAD3-dependent transcription of proline-biosynthesis genes, supporting proline supply for collagen production in cardiac myofibroblast-lineage cells. The supplied profile does not independently verify the journal name, but the scientific mechanism in the claim is supported.

1

Study evidence

BCAT1-mediated BCAA production promoted phosphorylation of HDAC5 at Ser488, which led to increased SMAD3 phosphorylation and enhanced SMAD3-dependent transcription of the proline-biosynthesis genes Aldh18a1, Pycr1, and Eprs in protomyofibroblast-like fibroblasts and myofibroblasts.

“The production of BCAA by BCAT1 promoted SMAD3 phosphorylation via HDAC5 phosphorylation at Ser488”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • At abstract depth, the mouse inhibitor experiment does not provide dose, route, treatment-timing details, sample size, effect magnitude, randomization/blinding information, or statistical detail.

    The story mentions the need to assess safety, dosing, and efficacy in future clinically applicable therapies, but it does not reflect that the abstract itself lacks key regimen and rigor details while the story presents a specific seven-day treatment claim.

    From in_vivo pharmacologic intervention (mouse MI model)

  • At abstract depth, cardiac functional preservation is not reported for the genetic-deficiency or inhibitor mouse experiments.

    The story repeatedly claims preserved or better heart function in mice, but the supplied abstract-level paper profile verifies fibrosis reduction only and notes that functional outcomes are unclear.

    From in vivo MI in BCAT1-deficient mice; in_vivo pharmacologic intervention (mouse MI model)

5 things the story did carry across
  • BCAT1 is upregulated in POSTN-expressing protomyofibroblast-like fibroblasts and in myofibroblasts in fibrotic hearts and livers of mice and humans.
  • BCAT1/BCAA metabolism promotes HDAC5 Ser488 phosphorylation, SMAD3 phosphorylation, and SMAD3-dependent transcription of proline-biosynthesis genes that support collagen production.
  • Genetic BCAT1 deficiency in mice after myocardial infarction attenuates proline-biosynthesis gene expression and decreases cardiac fibrosis.
  • Pharmacologic BCAT1 inhibition after myocardial infarction reduces cardiac fibrosis in mice.
  • Human tissue evidence is cross-sectional expression/localization evidence and supports association with fibrotic cell states, not causation in humans.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroMechanistic pathway: BCAT1/BCAA metabolism promotes HDAC5 Ser488 phosphorylation, increasing SMAD3 phosphorylation and SMAD3-dependent transcription of proline-biosynthesis genes (Aldh18a1, Pycr1, Eprs), supporting proline supply for collagen production in cardiac myofibroblasts.in vitro mechanistic cell experimentsExpand

In plain English

In protomyofibroblast-like fibroblasts and myofibroblasts, BCAT1-driven production of branched-chain amino acids (BCAAs) promoted phosphorylation of HDAC5 at Ser488, which was associated with increased SMAD3 phosphorylation and enhanced SMAD3-dependent transcription of proline-biosynthesis genes Aldh18a1, Pycr1, and Eprs, consistent with a BCAT1→HDAC5(Ser488)→SMAD3 signaling axis that upregulates proline-synthetic machinery.

Key findings

  • BCAT1-mediated BCAA production promoted phosphorylation of HDAC5 at Ser488, which led to increased SMAD3 phosphorylation and enhanced SMAD3-dependent transcription of the proline-biosynthesis genes Aldh18a1, Pycr1, and Eprs in protomyofibroblast-like fibroblasts and myofibroblasts.
“The production of BCAA by BCAT1 promoted SMAD3 phosphorylation via HDAC5 phosphorylation at Ser488”
What this piece can’t prove
  • The abstract does not specify whether the phosphorylation and transcriptional assays were performed in human versus mouse cells or both for the in vitro experiments.

2 further details could not be confirmed from the summary.

2ex vivo humanBCAT1 is upregulated in protomyofibroblast-like fibroblasts/myofibroblasts in fibrotic tissues (mouse and human), linking BCAT1 expression to the myofibroblast state in fibrosis.Cross-sectional ex vivo expression/localization profiling (immunostaining and/or transcript profiling) in mouse and human fibrotic tissuesExpand

In plain English

Abstract reports BCAT1 is upregulated in a substantial subset of Periostin (Postn)-expressing protomyofibroblast-like fibroblasts and in myofibroblasts in fibrotic hearts and livers of mice and humans.

Key findings

  • BCAT1 expression is reported as upregulated in a substantial subset of POSTN-expressing protomyofibroblast-like fibroblasts and in myofibroblasts in fibrotic hearts and livers of mice and humans.
“Bcat1 was upregulated in a substantial subset of Periostin (Postn)-expressing protomyofibroblast-like fibroblasts”
What this piece can’t prove
  • Summary is based solely on abstract text; full methods, figures, and quantitative data are not available here.
  • Unclear whether findings are consistent across all sampled specimens or limited to subsets.

2 further details could not be confirmed from the summary.

3in vivo animalIn vivo functional causality: genetic BCAT1 deficiency reduces post-MI proline-biosynthesis gene expression and decreases cardiac fibrosis.in vivo MI in BCAT1-deficient miceExpand

In plain English

In a mouse myocardial infarction (MI) model, genetic deficiency of BCAT1 reduced cardiac expression of proline-biosynthesis–related genes after MI and was associated with decreased cardiac fibrosis.

Key findings

  • In BCAT1-deficient mice, expression of proline biosynthesis–related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.
“In BCAT1-deficient mice, expression of proline biosynthesis-related genes was significantly attenuated in their hearts after myocardial infarction (MI), resulting in decreased cardiac fibrosis.”
4in vivo animalTherapeutic proof-of-concept: pharmacologic BCAT1 inhibition after MI reduces cardiac fibrosis.in vivo pharmacologic intervention (mouse MI model)Expand

In plain English

The abstract reports that pharmacologic inhibition of BCAT1 in mice after myocardial infarction (MI) reduced cardiac fibrosis, consistent with a potential therapeutic effect of BCAT1 inhibition on post-MI fibrosis.

Key findings

  • Pharmacologic BCAT1 inhibition after myocardial infarction reduced cardiac fibrosis in mice (reported in the abstract).
“mice with MI that were treated with a BCAT1 inhibitor had reduced cardiac fibrosis.”
What this piece can’t prove
  • Effect magnitude, variability, and reproducibility cannot be assessed from the information given.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Inhibitory Effect of Doxycycline on MMP2/9 and its Improvement in Cardiac Function and Left Ventricular Remodeling After Myocardial Infarction in Rats

Kafkas Universitesi Veteriner Fakultesi Dergisi · 2025 · Crossref

Source (opens in a new tab)
Candidate

Abstract 4365425: Mediation of the Relationship Between Myocardial Replacement Fibrosis and Sudden Cardiac Death by Left Ventricular Ejection Fraction Post-Myocardial Infarction

Circulation · 2025 · Crossref

Source (opens in a new tab)
Candidate

Anatomical, Functional, and Molecular Imaging of Left Ventricular Myocardial Infarction in Mice Using High Frequency Ultrasound

Crossref

Source (opens in a new tab)

And 9 more candidates considered.